A PHASE III TRIAL OF THE IMPACT OF SENTINEL LYMPH NODE MAPPING ON PATIENT REPORTED LOWER EXTREMITY LIMB DYSFUNCTION IN ENDOMETRIAL CANCER

Primary Investigator
L
Lisa Landrum, MD, PhD, MS

Primary Investigator

Recruiting
18 years - 100 years
Female
Phase 3
10 participants needed
2 Locations

Brief description of study

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.
 
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632

Detailed description of study

Patients are randomized to 1 of 2 arms:

  1. ARM 1: Patients receive ICG dye via injection and undergo sentinel lymph node mapping during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping cannot be completed. Successful mapping requires no additional removal of lymph nodes.
  2. ARM 2: Patients receive ICG dye via injection and undergo sentinel lymph node mapping during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care.

Patients in both arms also undergo imaging as clinically indicated.

After completion of study intervention, patients are followed every 3 months for one year and at 18 and 24 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Stage I Uterine Corpus Cancer AJCC v8
  • Age: 18 years - 100 years
  • Gender: Female

Inclusion Criteria:

  • Histologically proven diagnosis of endometrial cancer based on endometrial sampling with a plan to undergo laparoscopic or robotic hysterectomy and lymphatic assessment as part of primary management. Biopsy must be performed within 90 days prior to registration
  • Clinical stage I endometrial cancer based on the following diagnostic workup:
  • History/physical examination within 30 days prior to registration is reassuring for the absence of metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
  • Patients must speak English or Spanish

Updated on 23 Sep 2025. Study ID: CTO-NRG-CC010, 20357

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team